Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease affecting the mesothelium, commonly associated to asbestos exposure. The current therapeutic actions, based on cisplatin/pemetrexed treatment, are limited due to the late stage at which most patients are diagnosed and to...
Main Authors: | Rita Terenziani, Silvia Zoppi, Claudia Fumarola, Roberta Alfieri, Mara Bonelli |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/11/2793 |
Similar Items
-
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
by: Giulio Metro, et al.
Published: (2021-09-01) -
Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis
by: Maria Gemelli, et al.
Published: (2022-12-01) -
Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma
by: Lizbeth Rondon, et al.
Published: (2023-05-01) -
Immunotherapy in Malignant Pleural Mesothelioma
by: Cornedine J. de Gooijer, et al.
Published: (2020-02-01) -
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
by: Kazuya Tsubouchi, et al.
Published: (2020-04-01)